Dydrogesterone

Dydrogesterone has been studied in 22 papers since 2019: 5 observational studies in people, 15 reviews; 14 in the past year. It is an approved medicine. The newest paper, Nov 7, 2026: “Risk of colorectal cancer and systemic menopausal hormone therapies: a Finnish cohort study”.

InterventionApproved

22 papers study it7 more mention it10 findingsUpdated

PubChemChEBIMeSH

4 new papers in 30 daysSee all 29 papers on dydrogesterone

At a glance

The findings reach people, from one lab or study. 4 independent labs in 3 countries; 30 trials, 1 about aging, 10 with no results posted.

“and lowest for dydrogesterone (1.24, 1.03 to 1.48)”
Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databasesBMJ (Clinical research ed.)2020doi:10.1136/bmj.m3873

None of its findings points the other way.

Cells and humans: a single group. Worms or flies and mice: nothing yet.
  • 4 independent labs in 3 countries
  • 30 trials, 1 about aging, 10 with no results posted
  • Funders: Akdeniz University and others
  • 1 of 8 findings with company ties
  • 6 of 30 trials sponsored by its developers
  • Humans5

What did studies of dydrogesterone find?

6

Studies of dydrogesterone measured 6 outcomes, among them senescence marker expression, cell migration and FoxM1 expression.

Senescence marker expression

no changein human cells1

1 study
  1. Dydrogesterone showed no clear effect on senescence marker expression in human cells (Cells from women with recurrent pregnancy loss; DIO2 and β-GAL readouts).

    “neither treatment significantly reduced DIO2 or β-GAL expression.”

    CellsCells from women with recurrent pregnancy loss; DIO2 and β-GAL readoutsdecidual cellfemales

    Decidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment

    Reproductive biomedicine online

More on Senescence marker expression

Cell migration

upin human cells1

1 study
  1. Dydrogesterone increases cell migration in human cells (Co-culture with decidual cells from women with recurrent pregnancy loss).

    “MPA and DYD did not affect spheroid expansion in the RPL group but increased cell migration (p=0.009 and p<0.001, respectively)”

    CellsCo-culture with decidual cells from women with recurrent pregnancy lossAC-1M88 trophoblast-like cell co-culture

    Decidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment

    Reproductive biomedicine online

FoxM1 expression

upin human cells1

1 study
  1. Dydrogesterone increases FoxM1 expression in human cells (Cells from women with recurrent pregnancy loss).

    “MPA and DYD restored FOXM1 expression and improved decidual function, but did not reverse senescence marker expression.”

    CellsCells from women with recurrent pregnancy lossdecidual cellfemales

    Decidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment

    Reproductive biomedicine online

More on FoxM1 expression

Maternal complications and congenital anomalies

no changein humans1

1 study
  1. Dydrogesterone showed no clear effect on maternal complications and congenital anomalies in humans.

    “No maternal complications or congenital anomalies could be linked to dydrogesterone usage during ARTs or during early pregnancy to prevent recurrent miscarriages.”

    Reviewduring assisted reproductive techniques or early pregnancy to prevent recurrent miscarriages

    Dydrogesterone after 60 years: a glance at the safety profile

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Common adverse events

upin humans1

1 study
  1. Dydrogesterone increases common adverse events in humans.

    “However, other common AEs, such as headache, dizziness, abdominal pain, flatulence, and nausea, occurred more frequently with dydrogesterone.”

    Reviewfemales

    Dydrogesterone after 60 years: a glance at the safety profile

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Vagina-related adverse events

downin humans1

1 study
  1. Dydrogesterone decreases vagina-related adverse events in humans (luteal phase support during assisted reproductive techniques).

    “Vagina-related AEs, such as bleeding, discharge, irritation, and difficult coitus, occurred less frequently with dydrogesterone”

    Reviewluteal phase support during assisted reproductive techniquesvaginafemales

    Dydrogesterone after 60 years: a glance at the safety profile

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

What is dydrogesterone linked with?

3

Studies link dydrogesterone with 3 measures: breast cancer, colorectal cancer and venous thromboembolism.

Breast cancer

downin humans1upin humans1

2 studies
  1. Dydrogesterone is linked with a higher risk of breast cancer in humans (combined progestogen therapy, compared with never use) (odds ratio 1.24 (95% CI 1.03 to 1.48)).

    “and lowest for dydrogesterone (1.24, 1.03 to 1.48)”

    Humanscombined progestogen therapy, compared with never usefemalesn = 457,498

    Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases

    BMJ (Clinical research ed.)

  2. Dydrogesterone lowers the risk of breast cancer in estrogen-progestogen MHT compared to other combined MHT regimens.

    “Oestrogen-only MHT and oestrogen-progestogen MHT containing micronized progesterone or dydrogesterone are associated with lower breast cancer risk compared to other combined MHT regimens.”

    Reviewin estrogen-progestogen MHT compared to other combined MHT regimensbreastfemales

    Menopausal hormone therapy and breast cancer risk

    Best practice & research. Clinical endocrinology & metabolism

More on Breast cancer

Colorectal cancer

downin humans1

1 study
  1. Dydrogesterone is associated with colorectal cancer in humans (31–36% lower CRC risk).

    “Dydrogesterone EPT tended to confer 31–36% lower CRC risk than EPTs containing norethisterone or medroxyprogesterone acetate.”

    HumansCompared with estrogen-progestogen therapies containing norethisterone or medroxyprogesterone acetateComponent of estrogen-progestogen therapyfemales

    Risk of colorectal cancer and systemic menopausal hormone therapies: a Finnish cohort study

    Maturitas

More on Colorectal cancer

Venous thromboembolism

downin humans1

1 study
  1. Dydrogesterone lowers the risk of venous thromboembolism in humans (compared with other progestogens).

    “dydrogesterone may confer advantages in terms of venous thromboembolism and breast cancer risk”

    Reviewcompared with other progestogens

    Literature review of estradiol/dydrogesterone in perimenopausal and postmenopausal women

    Climacteric : the journal of the International Menopause Society

More on Venous thromboembolism

Has dydrogesterone been tested in people?

1 of 30 about aging

Yes: 5 observational studies in people have been published, and 30 trials are registered.

Approved

Every condition in trials

All 19

Stopped

  • NCT03858049TerminatedInfertility

    The trend in LPS treatment tends to increase the dosage of progesterone in FET-HRT, this study was designed 5 years ago.

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 3Mar 2026: 0Apr 2026: 1May 2026: 2Jun 2026: 1Jul 2026: 0Aug 2026: 2Sep 2026: 2Oct 2026: 3Nov 2026: 116 papers in 12 months

See all 29 papers on dydrogesterone